
|Videos|January 9, 2018
Achieving a Higher pCR Rate With Nab-Paclitaxel in Breast Cancer
Author(s)Christian Jackisch, MD, PhD
Christian Jackisch, MD, PhD, Professor of Obstetrics and Gynecology and Head of the Department of Obsterics and Gynaecology, Sana Klinikum Offenbach in Germany, discusses results of the GeparSepto study, as well as how a higher pathologic complete response (pCR) rate is achieved with nab-paclitaxel (Abraxane) in breast cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer
2
Exploring the IO Interface: Bridging Knowledge Gaps in Immunotoxicity Management
3
Medication Burden Linked With Acute Care Use in ARSI-Treated Prostate Cancer
4
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors
5








































